PPARD and psoriasis: Antagonism of PPARδ by topical application of GSK0660 in transgenic mice expressing Cyp1A1-driven expression of human PPARD in KCs and topically treated with the PPARδ agonist GW501516 (mouse model of psoriasis) reduced epidermal thickness, dermal inflammatory infiltrates with CD4+ and CD8+ T lymphocytes and expression of Il1b and Lce3e but failed to inhibit the expression of Hb-egf [100].